pharma · Acute myeloid leukemia · Juvenile idiopathic arthritis
Istituto Gentili Italia
Istituto Gentili S.r.l.
Istituto Gentili S.r.l is a pharma organization headquartered in MILANO, IT. Primary therapeutic focus areas include Acute myeloid leukemia, Juvenile idiopathic arthritis, Malignant Pleural Mesothelioma, Osteogenesis Imp
Via San Giuseppe Cottolengo, 15, Milano, Lombardia 20143, IT HQ
1917 Founded
121 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Via San Giuseppe Cottolengo, 15, Milano, Lombardia 20143, IT
- Founded
- 1917
- Employees
- 121
- Programs
- 50
- Drugs
- 114
- Patents
- 0
Cormeto 250 mg capsule molli
Approved · small molecule · patients with adrenal incidentalomas and subclinical/mild Cushing’s syndrome
Cormeto 250 mg capsule molli for patients with adrenal incidentalomas and subclinical/mild Cushing’s syndrome is a Approved program (small_molecule) at Istituto Gentili S.r.l. with 1 ClinicalTrials.gov record(s).
Internal code GR-MET-19
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Istituto Gentili S.r.l.
- Phase
- Approved
- Modality
- small_molecule
- Indication
- patients with adrenal incidentalomas and subclinical/mild Cushing’s syndrome
- Status
- active
- Trials
- 1